Advanced search
Publication Cover
Leukemia & Lymphoma Volume 45, 2004 - Issue 5
Submit an article Journal homepage
95
Views
32
CrossRef citations to date
0
Altmetric
Original Article

Bendamustine Plus Mitoxantrone—A New Effective Treatment for Advanced Chronic Lymphocytic Leukaemia: Results of a Phase I/II Study

Hubert Köppler Haematology/Oncology Group Practice, Nevers Straße 5, 56068 Koblenz, Germany
,
Jochen Heymanns Haematology/Oncology Group Practice, Nevers Straße 5, 56068 Koblenz, Germany
,
Annette Pandorf Haematology/Oncology Group Practice, Nevers Straße 5, 56068 Koblenz, Germany
&
Rudolf Weide Haematology/Oncology Group Practice, Nevers Straße 5, 56068 Koblenz, Germany
Pages 911-913 | Received 14 Apr 2003, Published online: 22 Nov 2010

Citations (32)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (11)

Loretta J Nastoupil, Rajni Sinha & Christopher R Flowers. (2013) The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy. Expert Review of Anticancer Therapy 13:9, pages 1089-1108.
Read now
Rudolf Weide, Stefan Feiten, Vera Friesenhahn, Jochen Heymanns, Kristina Kleboth, Jörg Thomalla, Christoph van Roye & Hubert Köppler. (2013) Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leukemia & Lymphoma 54:8, pages 1640-1646.
Read now
Marco Montillo & Alessandra Tedeschi. (2013) ‘Use it again!’: retherapy with bendamustine in indolent B-cell lymphoproliferative disorders. Expert Review of Hematology 6:3, pages 247-250.
Read now
Anna Korycka-Wołowiec & Tadeusz Robak. (2012) Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1455-1468.
Read now
John L Reagan & Jorge J Castillo. (2011) Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 11:2, pages 151-160.
Read now
Chaitra Ujjani & Bruce D Cheson. (2010) Bendamustine in chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Expert Review of Anticancer Therapy 10:9, pages 1353-1365.
Read now
Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Eleonora Vismara & Enrica Morra. (2010) Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Review of Hematology 3:2, pages 131-148.
Read now
Saad Jamshed & Bruce D Cheson. (2009) Role of bendamustine in the treatment of chronic lymphocytic leukemia. OncoTargets and Therapy 2, pages 43-49.
Read now
David Masiello & Anil Tulpule. (2009) Bendamustine therapy in chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy 10:10, pages 1687-1698.
Read now
Ibrahim T Aldoss, Susan M Blumel & Philip J Bierman. (2009) The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma. Cancer Management and Research 1, pages 155-165.
Read now
Wolfgang Knauf. (2009) Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 9:2, pages 165-174.
Read now

Articles from other publishers (21)

Wenhua Chen, Limin Zou, Fei Zhang, Xiangyang Xu, Liandi Zhang, Mingyi Liao, Xiaoqiang Li & Li Ding. (2015) Determination and Characterization of Two Degradant Impurities in Bendamustine Hydrochloride Drug Product. Journal of Chromatographic Science 53:10, pages 1673-1679.
Crossref
Norbert Niederle, Dirk Megdenberg, Leopold Balleisen, Wolfgang Heit, Wolfgang Knauf, Johann Weiß, Werner Freier, Axel Hinke, Stefan Ibach & Hartmut Eimermacher. (2013) Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Annals of Hematology 92:5, pages 653-660.
Crossref
Hubert Köppler, Harald Fuss, Hans J. Hurtz, Owe Knigge, Christoph Losem, Daniel Reschke, Stephan Schmitz, Rudolf Weide, Johann Weiß & Michael Hallek. (2012) Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG). British Journal of Haematology 158:2, pages 238-241.
Crossref
Blanca Sanchez-Gonzalez, F. Javier Peñalver, Angeles Medina, Helga Guillén, Marta Calleja, Mercedes Gironella, Reyes Arranz, Elena Sebastian, Raquel de Oña, Araceli Cánovas, Ignacio de la Fuente, Carlos Grande, Juan Manuel Sancho, Ricardo Perez, Eva Domingo, José Luis Lopez-Lorenzo, Elena Prieto, Carlos Panizo, Ana Gorosquieta, Inmaculada Perez, Jose Manuel Cervera, Miguel Marin, Carmen Mencha, Elena Ramila & Antonio Salar. (2012) Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain. Leukemia Research 36:6, pages 709-714.
Crossref
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Ana Maria Scutaru, Maxi Wenzel & Ronald Gust. (2011) Bivalent bendamustine and melphalan derivatives as anticancer agents. European Journal of Medicinal Chemistry 46:5, pages 1604-1615.
Crossref
Mathias J. Rummel & Stephanie A. Gregory. (2011) Bendamustine's Emerging Role in the Management of Lymphoid Malignancies. Seminars in Hematology 48, pages S24-S36.
Crossref
Valentin Goede & Michael Hallek. (2011) Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia. Drugs & Aging 28:3, pages 163-176.
Crossref
Valentin Goede, Barbara Eichhorst & Michael Hallek. 2010. Leukemias: Principles and Practice of Therapy. Leukemias: Principles and Practice of Therapy 308 314 .
Amy Hatfield Seung. (2010) Standard of care and novel treatments for chronic lymphocytic leukemia. American Journal of Health-System Pharmacy 67:21, pages 1813-1824.
Crossref
Marina Motta, William G. Wierda & Alessandra Ferrajoli. (2009) Chronic lymphocytic leukemia. Cancer 115:17, pages 3830-3841.
Crossref
Matt Kalaycio. (2009) Bendamustine. Cancer 115:3, pages 473-479.
Crossref
Trevor W. Dennie & Jill M. Kolesar. (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma. Clinical Therapeutics 31, pages 2290-2311.
Crossref
Valentin Goede & Michael Hallek. (2008) Current Treatment for Chronic Lymphocytic Leukemia. Clinical Leukemia 2:4, pages 230-236.
Crossref
Matt Kalaycio. (2008) Clinical Experience with Bendamustine: A New Treatment for Patients with Chronic Lymphocytic Leukemia. Clinical Leukemia 2:4, pages 223-229.
Crossref
Nicole Lamanna. (2008) Chronic Lymphocytic Leukemia: An Amazing Time Given the Development of New Combination Therapies and New Agents, but Still No Cure, and a Need to Focus on Patient-Specific Treatment Options. Clinical Leukemia 2:4, pages 221-222.
Crossref
Gaël Roué, Mónica López-Guerra, Pierre Milpied, Patricia Pérez-Galán, Neus Villamor, Emili Montserrat, Elias Campo & Dolors Colomer. (2008) Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling. Clinical Cancer Research 14:21, pages 6907-6915.
Crossref
Jame Abraham. (2008) Bendamustine in chronic lymphocytic leukemia. Community Oncology 5:3, pages 133-134.
Crossref
Jonathan W. FriedbergPhilip CohenLing ChenK. Sue RobinsonAndres Forero-TorresAnn S. La CasceLuis E. FayadAlberto BessudoElber S. CamachoMichael E. WilliamsRichard H. van der JagtJennifer W. OliverBruce D. Cheson. (2008) Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study. Journal of Clinical Oncology 26:2, pages 204-210.
Crossref
M. Leithäuser & M. Freund. 2007. Therapiekonzepte Onkologie. Therapiekonzepte Onkologie 342 384 .
Emili MontserratCarol MorenoJordi EsteveAlvaro Urbano-IspizuaEva GinéFrancesc Bosch. (2006) How I treat refractory CLL. Blood 107:4, pages 1276-1283.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.